Want to see RNTX full AI Analyst Report?
RNTX Stock Chart & Stats
$1.26
--
Market closed
$1.26
--
Day’s Range― - ―
52-Week Range$0.85 - $2.18
Previous CloseN/A
VolumeN/A
Average Volume (3M)228.95K
Market Cap
$73.74M
Enterprise Value$84.94
Total Cash (Recent Filing)$4.45M
Total Debt (Recent Filing)$4.92M
Price to Earnings (P/E)―
Beta1.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding85,539,030
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside534.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Extended Runway From FinancingThe $50M underwritten offering materially extends runway into 2028, enabling Rein to fully fund its Phase 2 LTI-03 program and near-term operations. This reduces immediate liquidity pressure and lets management prioritize clinical execution and milestone delivery instead of urgent fundraising.
Modest LeverageLow absolute debt relative to equity implies modest financial leverage, which preserves optionality for non-dilutive financing or structured debt if needed. This balance sheet posture provides flexibility while clinical programs advance and reduces near-term creditor pressure on operations.
Focused Clinical StrategyA concentrated focus on pulmonary diseases and IPF creates deep scientific expertise and strategic clarity. This specialization can attract targeted partners, grant or programmatic funding, and aligned R&D resources, improving chances to translate clinical success into sizable long-term value.
Bears Say
No Revenue; Large LossesThe absence of commercial revenue and sizable recurring net losses means the company is wholly dependent on capital markets or partnerships to fund operations. This structural reliance increases dilution risk and ties the firm's viability to successful trial outcomes or external financing.
Persistent Negative Cash FlowSustained negative operating and free cash flow forces repeated fundraising and limits strategic flexibility. Ongoing cash burn constrains R&D expansion and makes program continuity sensitive to market access for capital, creating execution risk if financing conditions tighten or trials delay.
Eroding Equity BaseSharp declines in shareholder equity and deeply negative ROE reflect cumulative losses and past financing impacts. A thinner equity buffer reduces resilience to adverse trial results or funding gaps and often necessitates further dilution or onerous financing terms to sustain operations.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $0.85 and its highest was $2.18 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $73.74M.
When is Rein Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rein Therapeutics’s earnings last quarter?
Currently, no data Available
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 85,539,030 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (534.92% Upside)
$8.00 (534.92% Upside)
Insider Transactions
Bought Shares
Worth $74.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.80%
12-Months-Change
Fundamentals
Return on Equity
-258.45%
Trailing 12-Months
Asset Growth
-54.38%
Trailing 12-Months
Company Description
Rein Therapeutics
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
RNTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(534.92% Upside)
Technical Analysis
Ownership Overview
1.78% Insiders
1.38% Mutual Funds
11.00% Other Institutional Investors
81.77% Public Companies and
Individual Investors